CD229/SLAMF3 Protein, Human (Biotinylated, HEK293, His-Avi)

CD229/SLAMF3 Protein, a self-ligand receptor in the SLAM family, modulates immune cell activation and differentiation through cell interactions. Crucial for innate and adaptive immune responses, its activities are controlled by SH2D1A/SAP and/or SH2D1B/EAT-2. It mediates T-cell adhesion, promotes Th17 differentiation with IL-17 secretion requiring SH2D1A, and facilitates RORC recruitment to the IL-17 promoter. CD229/SLAMF3 acts as a negative immune regulator, inhibiting autoantibody responses and CD4(+) T-cell IFN-gamma secretion. It regulates thymic innate CD8(+) T-cell size and iNKT cell development, interacting with SH2D1A, SH2D1B, INPP5D, and PTPN11, blocking PTPN11 interaction with SH2D1A. CD229/SLAMF3 Protein, Human (Biotinylated, HEK293, His-Avi) is the recombinant human-derived CD229/SLAMF3 protein, expressed by HEK293, with C-Avi, C-His labeled tag. The total length of CD229/SLAMF3 Protein, Human (Biotinylated, HEK293, His-Avi) is 407 a.a., with molecular weight of 70-80 kDa.

CD229/SLAMF3 Protein is a self-ligand receptor that belongs to the signaling lymphocytic activation molecule (SLAM) family. It functions as a modulator of immune cell activation and differentiation through homo- or heterotypic cell-cell interactions. This receptor plays a crucial role in regulating both innate and adaptive immune responses. The presence or absence of small cytoplasmic adapter proteins, SH2D1A/SAP and/or SH2D1B/EAT-2, controls its activities. CD229/SLAMF3 is involved in adhesion reactions between T lymphocytes and accessory cells through homophilic interactions. It promotes the differentiation of T-cells into a helper T-cell Th17 phenotype, leading to increased secretion of IL-17, with the costimulatory activity requiring SH2D1A. Furthermore, it facilitates the recruitment of RORC to the IL-17 promoter. CD229/SLAMF3 may also function as a negative regulator of the immune response, contributing to the maintenance of peripheral cell tolerance. It can inhibit autoantibody responses and IFN-gamma secretion by CD4(+) T-cells. Additionally, it is involved in regulating the size of thymic innate CD8(+) T-cells and the development of invariant natural killer T (iNKT) cells. CD229/SLAMF3 interacts with SH2D1A, SH2D1B, INPP5D, and PTPN11, with the interaction with PTPN11 being blocked by SH2D1A.

Human

HEK293

C-Avi;C-His

Q9HBG7-1 (K48-K454)

4063  [NCBI]

70-80 kDa

Greater than 95% as determined by reducing SDS-PAGE.

<1 EU/μg, determined by LAL method.